Cancer Cell

Oncology

Zetagen is committed to the treatment of metastatic cancer lesions to bone and other soft tissue organs. Bone metastases are common among cancer patients and occur when cells from the primary cancerous tumor relocate to the bone. When these cancers relocate, they can cause changes to the bone, damaging it in a process called osteolysis. Osteolysis can cause small holes within the bone, weakening it and increasing the risk of breakage. These holes are called “lytic lesions.” Among cancers which metastasize to bone, Breast and Prostate are most prevalent, amounting to approximately 70-percent of cases.[1]

Lytic lesions can cause severe, debilitating pain in patients with advanced cancer. Patients with these lesions often experience a reduced quality of life with multiple skeletal-related events (SREs), including fractures, spinal cord compression, elevated levels of calcium in the blood or “hypercalcaemia”, bone marrow infiltration and severe bone pain.[2] Bone metastases are also a major cause for morbidity in patients with advanced stage cancer.[3]

The Standard of Care (SOC) prescribes external single or fractionated radiation therapy (RT) as a palliative procedure to manage pain, that on average provides durable effective pain relief for six (6) months[1,2]. The median survival rate following the SOC RT for metastases to bone is between 5 to 9 months [2,3]. The SOC RT has not been shown to change the likelihood of preventing pathologic fracture[4]. The survival rate following a skeletal related event (SRE) that includes fracture is 4.8 months following the SOC.[5]

  1. Arnalot PF, Fontanals AV, JC Galceran, Lynd F, Latiesas S, Rodriguez de Dios, Castillejo AR, Bassols ML, Galan JL, Conejo IM, Lopez MA. Randomized clinical trial with two palliative radiotherapy regimens in painful bone metastases: 30 Gy in 10 fractions compared with 8 Gy in single fraction. Radiother Oncol. 2008; 89: 150–55.
  2. Hayashi S, Tanaka H, Hoshi H. External beam radiotherapy for painful bone metastases from hepatocellular carcinoma: multiple fractions compared with an 8-Gy single fraction. Nagoya J Med Sci. 2014 Feb;76(1-2):91-9.
  3. Zacharia B, Joy J, Subramaniam D, Pai PK. Factors Affecting Life Expectancy After Bone Metastasis in Adults - Results of a 5-year Prospective Study. Indian J Surg Oncol. 2021 Dec;12(4):759-769. doi: 10.1007/s13193-021-01426-1. Epub 2021 Aug 30.
  4. Spencer K, Velikova G, Henry A, Westhoff P, Hall PT, van der Linden YM. Net Pain Relief After Palliative Radiation Therapy for Painful Bone Metastases: A Useful Measure to Reflect Response Duration? A Further Analysis of the Dutch Bone Metastasis Study. Int J Radiat Oncol Biol Phys. 2019 Nov 1;105(3):559-566.
  5. Howell SJ, Casbard A, Carucci M et al. Fulvestrant plus capivasertib versus placebo after relapse or progression on an aromatase inhibitor in metastatic, oestrogen receptor-positive, HER2-negative breast cancer (FAKTION): overall survival, updated progression-free survival, and expanded biomarker analysis from a randomised, phase 2 trial. Lancet Oncol. 23, 851–864 (2022).

Our product, ZetaMet™ (Zeta-BC-003) has thus far demonstrated its ability to resolve existing metastatic bone lesions, inhibit pain, stimulate targeted bone regeneration with the potential increase survival rates.

About
zetamet-logo

ZetaMet™ 
(Zeta-BC-003)

ZetaMet™ (Zeta-BC-003) is a synthetic, small-molecule, developed via a proprietary control release carrier developed to resolve bone lesions, inhibiting pain while regenerating bone, with the potential to increase survival rates. The U.S. Food and Drug Administration recently awarded ZetaMet™ (Zeta-BC-003) Breakthrough Designation for the treatment of metastatic bone cancer. Currently, ZetaMet™ (Zeta-BC-003) has been approved by Health Canada for a clinical trial which is currently enrolling for the treatment of metastatic breast cancer lesions to the spine. Zetagen scientists have discovered an entirely new pathway for this established molecule which, if proven successful in human clinical trials, could create a new treatment paradigm for patients living with metastatic bone lesions.
zetamet-product
About

ZetaMet-P™ 
(Zeta-PC-004)

ZetaMet-P™ (Zeta-PC-004) is a synthetic, small-molecule, antitumorigenic therapy, administered locally, being developed to target and resolve metastatic prostate cancer bone lesions while inhibiting future tumor growth. The small molecule has been approved by the U.S. Food and Drug Administration (FDA) since 1971 and has an extensive safety profile.
About

ZetaMast™ 
(Zeta-MBC-005)

ZetaMAST™ (Zeta-MBC-005) is a proprietary novel drug being designed for patients with unresectable, multifocal breast cancer metastases to the liver, lung, or brain. ZetaMAST™ (Zeta-MBC-005) can be administered as a percutaneous injection utilizing a proprietary hydrogel carrier containing a precise, tailored concentration of our small molecule. Preclinical studies have demonstrated ZetaMAST™ (Zeta-MBC-005) may cease lesion growth, with the goal of enabling improved quality of life as part of a cancer treatment program, including longevity.
zetbase-bone-graft
About
zetamet-flowable

ZetaBase®

ZetaBase® is the carrier for ZetaMet™ (Zeta-BC-003) and is osteo-conductive and osteo-promotive, specifically formulated to aid bone healing in the treatment of metastatic lytic bone lesions. ZetaBase® may also be used as a bone void filler and or bone graft extender to fill bony voids or gaps that are not intrinsic to the stability of bony structures. ZetaBase® Bone Graft will be available in various sizes and is provided sterile, non-pyrogenic, and for single use only.
About
zetamet-logo

ZetaMet™ 
(Zeta-BC-003)

ZetaMet™ 
(zetaX003)

ZetaMet™ (Zeta-BC-003) is a synthetic, small-molecule, developed via a proprietary control release carrier developed to resolve bone lesions, inhibiting pain while regenerating bone, with the potential to increase survival rates. The U.S. Food and Drug Administration recently awarded ZetaMet™ (Zeta-BC-003) Breakthrough Designation for the treatment of metastatic bone cancer. Currently, ZetaMet™ (Zeta-BC-003) has been approved by Health Canada for a clinical trial which is currently enrolling for the treatment of metastatic breast cancer lesions to the spine. Zetagen scientists have discovered an entirely new pathway for this established molecule which, if proven successful in human clinical trials, could create a new treatment paradigm for patients living with metastatic bone lesions.
zetamet-product
About

ZetaMet-P™ 
(zetaX004)

ZetaMet-P™ 
(Zeta-PC-004)

ZetaMet-P™ (Zeta-PC-004) is a synthetic, small-molecule, antitumorigenic therapy, administered locally, being developed to target and resolve metastatic prostate cancer bone lesions while inhibiting future tumor growth. The small molecule has been approved by the U.S. Food and Drug Administration (FDA) since 1971 and has an extensive safety profile.
About

ZetaMAST™
(Zeta-MBC-005)

ZetaMAST™ 
(zetaX005)

ZetaMAST™ (Zeta-MBC-005) is a proprietary novel drug being designed for patients with unresectable, multifocal breast cancer metastases to the liver, lung, or brain. ZetaMAST™ (Zeta-MBC-005) can be administered as a percutaneous injection utilizing a proprietary hydrogel carrier containing a precise, tailored concentration of our small molecule. Preclinical studies have demonstrated ZetaMAST™ (Zeta-MBC-005) may cease lesion growth, with the goal of enabling improved quality of life as part of a cancer treatment program, including longevity.
About
zetamet-flowable

ZetaBase®

ZetaBase® is the carrier for ZetaMet™ (Zeta-BC-003) and is osteo-conductive and osteo-promotive, specifically formulated to aid bone healing in the treatment of metastatic lytic bone lesions.  ZetaBase® may also be used as a bone void filler and or bone graft extender to fill bony voids or gaps that are not intrinsic to the stability of bony structures. ZetaBase® Bone Graft will be available in various sizes and is provided sterile, non-pyrogenic, and for single use only.
zetbase-bone-graft